{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:13:22Z","timestamp":1788477202245,"version":"build-2803163510"},"reference-count":116,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare, aggressive B-cell lymphoma, sharing common features with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). PMLBCL is usually cured with single-hit immunochemotherapy in the first-line setting. Relapses tend to be aggressive and may be unresponsive to conventional chemotherapy. Autologous stem cell transplant (ASCT) remains a viable option for chemosensitive patients; nevertheless, targeted therapies appear to be highly promising. Checkpoint inhibitors (CPIs) have already transformed the course of relapse\/refractory disease, while CD-19-directed Chimeric Antigen Receptor (CAR) T-cell therapy may produce remarkably favorable outcomes. The exact position of CAR T-cells and CPIs in the treatment algorithm, along with the role of radiotherapy and ASCT, remains to be precisely determined. In the current review, we aim to present the recent research on targeted agents in PMLBCL and define their sequencing within the treatment algorithm, mainly in the relapse\/refractory setting.<\/jats:p>","DOI":"10.3390\/jcm14041191","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:54:06Z","timestamp":1739274846000},"page":"1191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Athanasios","family":"Liaskas","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens \u201cLaikon\u201d, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N.","family":"Dimopoulou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens \u201cLaikon\u201d, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Piperidou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens \u201cLaikon\u201d, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens \u201cLaikon\u201d, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-1853","authenticated-orcid":false,"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens \u201cLaikon\u201d, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Publications. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2001.19.6.1855","article-title":"Primary mediastinal B-cell lymphoma: A review of pathology and management","volume":"19","author":"Kelta","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Karakatsanis, S., Hellenic Cooperative Lymphoma Group, Papageorgiou, S.G., Michail, M., Angelopoulou, M.K., Kalpadakis, C., Leonidopoulou, T., Katodritou, E., Kotsopoulou, M., and Kotsianidis, I. (2021). Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: An impressive, rare presentation with no independent effect on prognosis. Leuk. Res., 107.","DOI":"10.1016\/j.leukres.2021.106595"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2012","article-title":"Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab","volume":"31","author":"Papageorgiou","year":"2013","journal-title":"Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.1999.17.8.2479","article-title":"CNS involvement in primary mediastinal large B-cell lymphoma","volume":"17","author":"Bishop","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO-24-01373","article-title":"Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results","volume":"42","author":"Martelli","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_9","first-page":"1258","article-title":"Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients","volume":"87","author":"Zinzani","year":"2002","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdj030","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience","volume":"17","author":"Savage","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2141.2005.05661.x","article-title":"Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999","volume":"130","author":"Hamlin","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_12","first-page":"187","article-title":"Primary mediastinal large B-cell lymphoma with sclerosis: A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy","volume":"86","author":"Zinzani","year":"2001","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.bjc.6601460","article-title":"Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B\/VACOP-B","volume":"90","author":"Todeschini","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00277-008-0625-2","article-title":"Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate","volume":"88","author":"Fietz","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dunleavy, K., Pittaluga, S., Janik, J., Grant, N., Shovlin, M., Steinberg, S., Raffeld, M., Staudt, L., Jaffe, E.S., and Wilson, W.H. (2006). Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients. Blood, 108.","DOI":"10.1182\/blood.V108.11.209.209"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/onco.13789","article-title":"Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP","volume":"26","author":"Vassilakopoulos","year":"2021","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: The emerging standard of care","volume":"17","author":"Vassilakopoulos","year":"2012","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.14287","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: A subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial","volume":"175","author":"Gleeson","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","article-title":"Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: A LYSA study","volume":"5","author":"Camus","year":"2021","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.21873\/invivo.12831","article-title":"Real-life Experience with Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma","volume":"36","author":"Karakatsanis","year":"2022","journal-title":"In Vivo"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Thurner, L., Ziepert, M., Berdel, C., Schmidt, C., Borchmann, P., Kaddu-Mulindwa, D., Viardot, A., Witzens-Harig, M., Dierlamm, J., and Haenel, M. (2023). Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study. Hemasphere, 7.","DOI":"10.1097\/HS9.0000000000000904"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.15051","article-title":"R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: A multi-centre analysis","volume":"180","author":"Shah","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1002\/cam4.2347","article-title":"Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma","volume":"8","author":"Chan","year":"2019","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ejh.13337","article-title":"Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma","volume":"104","author":"Malenda","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Chen","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/hon.3164_301","article-title":"Real-Life Experience with Rituximab-Dose-Adjusted Epoch (R-Da-Epoch) In Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl): A Multinational Analysis Of 274 Patients","volume":"41","author":"Vassilakopoulos","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Piperidou, A., Mellios, Z., Verigou, E., Katodritou, E., Kalpadakis, C., Papageorgiou, S.G., Chatzidimitriou, C., Prassopoulos, V., and Siakantaris, M.P. (2023). PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?. Hemasphere, 7.","DOI":"10.1097\/HS9.0000000000000965"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chatzidimitriou, C., Rondogianni, P., Arapaki, M., Liaskas, A., Plata, E., Angelopoulou, M.K., Tsirigotis, P., and Vassilakopoulos, T.P. (2021). Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma. Medicina, 58.","DOI":"10.3390\/medicina58010048"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hon.3096","article-title":"Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era","volume":"41","author":"Vassilakopoulos","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.V91.2.717","article-title":"Primary diffuse large B-cell lymphoma of the mediastinum: Outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation","volume":"91","author":"Sehn","year":"1998","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Aoki, T., Shimada, K., Suzuki, R., Izutsu, K., Tomita, A., Maeda, Y., Takizawa, J., Mitani, K., Igarashi, T., and Sakai, K. (2015). High-dose chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J., 5.","DOI":"10.1038\/bcj.2015.101"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","article-title":"Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant","volume":"24","author":"Vardhana","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41409-017-0063-7","article-title":"Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: Long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation","volume":"53","author":"Avivi","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jtct.2023.08.019","article-title":"High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"29","author":"Alkhaldi","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.bbmt.2019.07.041","article-title":"Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma","volume":"25","author":"Herrera","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Chatzidimitriou, C., Asimakopoulos, J.V., Arapaki, M., Tzoras, E., Angelopoulou, M.K., and Konstantopoulos, K. (2019). Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers, 11.","DOI":"10.3390\/cancers11081071"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41416-023-02363-2","article-title":"PD-1 receptor outside the main paradigm: Tumour-intrinsic role and clinical implications for checkpoint blockade","volume":"129","author":"Donini","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Armand, P., Rodig, S.J., Melnichenko, V., Thieblemont, C., Bouabdallah, K., Tumyan, G., \u00d6zcan, M., Portino, S., Fogliatto, L., and Caballero, D. (2018). Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. Blood, 132.","DOI":"10.1182\/blood-2018-99-110220"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_45","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: Final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10147-024-02627-8","article-title":"Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: Results from the KEYNOTE-A33 study","volume":"29","author":"Kato","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"McDonald, A.B., Verburgh, E., Gotti, M., Pinto, A., Zaucha, J.M., Ivanov, V., Melnichenko, V., Mocikova, H., Ozcan, M., and Patti, C. (2023). Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed\/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma. Blood, 142.","DOI":"10.1182\/blood-2023-186800"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Liaskas, A., Pereyra, P., Panayiotidis, P., Angelopoulou, M.K., and Gallamini, A. (2023). Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713187"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Asimakopoulos, J.V., Konstantopoulos, K., and Angelopoulou, M.K. (2020). Optimizing outcomes in relapsed\/refractory Hodgkin lymphoma: A review of current and forthcoming therapeutic strategies. Ther. Adv. Hematol., 11.","DOI":"10.1177\/2040620720902911"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: Results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Heiser, R.A., Grogan, B.M., Manlove, L.S., and Gardai, S.J. (2018). Abstract 1789: CD30+T regulatory cells, but not CD30+CD8 T cells, are impaired following brentuximab vedotin treatment in vitro and in vivo. Cancer Res., 78.","DOI":"10.1158\/1538-7445.AM2018-1789"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1182\/bloodadvances.2023010254","article-title":"Nivolumab combined with brentuximab vedotin for R\/R primary mediastinal large B-cell lymphoma: A 3-year follow-up","volume":"7","author":"Zinzani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_60","first-page":"3019","article-title":"Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"109","author":"Renaud","year":"2024","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_63","first-page":"3563","article-title":"Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma","volume":"5","author":"Crombie","year":"2021","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","article-title":"Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: The Italian CART-SIE study","volume":"38","author":"Chiappella","year":"2024","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1182\/bloodadvances.2023011203","article-title":"Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: A GLA\/DRST registry study","volume":"7","author":"Schubert","year":"2023","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.HS9.0000847752.29527.f6","article-title":"P1222: Pacific: Brentuximab Vedotin and Nivolumab Alone and Then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Untreated Primary Mediastinal Large B-Cell Lymphoma Patients","volume":"6","author":"Steiner","year":"2022","journal-title":"HemaSphere"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: Potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.clml.2023.10.002","article-title":"Pembrolizumab with R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety with Long-Term Follow-Up","volume":"24","author":"Ho","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: A paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00277-021-04421-2","article-title":"Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: Impact on outcomes and radiotherapy strategies","volume":"100","author":"Vassilakopoulos","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.clml.2023.08.014","article-title":"Updates in the Management of Primary Mediastinal B Cell Lymphoma","volume":"23","author":"Soueidy","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_86","unstructured":"(2024, December 14). B-Cell Lymphomas (Version 3.2024). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Lee, H.J., Forman, S.J., Kwak, L.W., Rosen, S., Song, J.Y., Ortega, R., McBride, K., Nikolaenko, L., Nademanee, A.P., and Popplewell, L.L. (2019). PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. Blood, 134.","DOI":"10.1182\/blood-2019-123162"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00277-023-05470-5","article-title":"Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical Hodgkin\u2019s lymphoma and primary mediastinal B cell lymphoma","volume":"103","author":"Panda","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study","volume":"35","author":"McMillan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: Refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.21873\/invivo.12639","article-title":"Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review","volume":"35","author":"Dimou","year":"2021","journal-title":"In Vivo"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-019-0657-3","article-title":"Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma","volume":"55","author":"Hill","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","article-title":"Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 US institutions","volume":"7","author":"Major","year":"2023","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2012.077917","article-title":"Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas","volume":"98","author":"Korfel","year":"2013","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clml.2024.07.019","article-title":"Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis","volume":"25","author":"Okcu","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hon.66_2880","article-title":"Prognostic Factors, Management and Outcome of an International Series of 41 Patients with Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl) and Central Nervous System (Cns) Involvement","volume":"39","author":"Ferreri","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hon.2836","article-title":"Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement","volume":"39","author":"Nunez","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/10428194.2024.2396043","article-title":"Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: Case report and review of the literature","volume":"65","author":"Shaulov","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Luttwak, E., Cassanello, G., Brown, S., Devlin, S.M., Imber, B.S., Ip, A., Leslie, L.A., Golan Accav, N., Beyar-Katz, O., and Corona, M. (2024). CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease. Blood, 144.","DOI":"10.1182\/blood-2024-212274"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1182\/bloodadvances.2023010336","article-title":"Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: A GLA\/DRST study","volume":"7","author":"Ayuk","year":"2023","journal-title":"Blood Adv."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hon.2377","article-title":"Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors","volume":"35","author":"Alfo","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.23.01053","article-title":"Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes","volume":"42","author":"Noerenberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10428194.2021.2010060","article-title":"Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: A retrospective study","volume":"63","author":"Camus","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.18809","article-title":"Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort","volume":"202","author":"Roulin","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood.2022015601","article-title":"Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"140","author":"Cherng","year":"2022","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.1182\/blood-2022-162814","article-title":"Detection of Early Molecular Response (EMR) and Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using a Validated Next Generation Sequencing (NGS) Assay for the Detection of Tumor Variants in Circulating Tumor (ct)DNA","volume":"140","author":"Stokowski","year":"2022","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients with Hodgkin Lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:38Z","timestamp":1760027498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":116,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041191"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041191","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}